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Shimizu and Datedoi:10.1016/j.jtcvs.2004.07.032Objective: Survival after living-donor lobar lung transplantation has been reported
to be similar to that after cadaveric lung transplantation. The purpose of this study
was to summarize our 5-year experience of living-donor lobar lung transplantation
for critically ill patients.
Methods: Between October 1998 and April 2004, we performed living-donor
lobar lung transplantation in 30 critically ill patients with various lung diseases,
including 5 (17%) patients on a ventilator. Mean age was 30.4 years (range, 8-55
years). Postoperative management included slow weaning from a ventilator,
relatively low-dose immunosuppressants, and careful rejection monitoring on
the basis of radiographic and clinical findings without transbronchial lung
biopsy.
Results: The average duration of mechanical ventilation was 15.4 days, intensive
care unit stay was 23.5 days, and hospital stay was 64.6 days. Clinically judged
acute rejection occurred at an average rate of 1.5 episodes per patient, but infection
occurred in only one patient during the first month. In spite of the complicated
postoperative course, all patients were discharged without oxygen inhalation. Four
patients had unilateral bronchiolitis obliterans syndrome, but the decrease in their
forced expiratory volume in 1 second values stopped within 9 months. All 30
recipients are currently alive, with a follow-up period of 1 to 66 months. All donors
have returned to their previous lifestyles.
Conclusions: Living-donor lobar lung transplantation can be applied to both pedi-
atric and adult patients with very limited life expectancies. It might provide better
survival than conventional cadaveric lung transplantation.
Lung transplantation has been performed internationally as an effec-tive treatment for a variety of end-stage lung diseases. A greatdisparity between the supply of donor organs and the demand ofpotential recipients has resulted in longer waiting times and annualincreases in deaths on the lung transplant waiting list. As a conse-quence, efforts have been directed toward the use of marginal
donors,1,2 non–heart-beating donors,3 and living donors.4-8
Bilateral living-donor lobar lung transplantation (LDLLT) was clinically devel-
oped at the University of Southern California as a procedure for patients considered
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report from this group, the overall actuarial survival of 123
LDLLT recipients was 45% at 5 years.7
Stimulated by their pioneering work, we began a pro-
gram of LDLLT at Okayama University Hospital in October
1998.8 The purpose of this study was to summarize our
5-year experience in LDLLT for 30 consecutive patients
with limited life expectancy.
Methods
Patient and Donor Selection
All recipients fulfilled the criteria for conventional bilateral lung
transplantation. We have accepted only critically ill patients as
candidates for LDLLT and only relatives within the second degree
or a spouse as living donors. Each case was carefully reviewed by
the Lung Transplant Evaluation Committee at Okayama Univer-
sity Hospital. Regarding the size matching, we have previously
proposed a formula to estimate the graft forced vital capacity
(FVC) on the basis of the donor’s measured FVC and the number
of pulmonary segments implanted.8 When the total FVC of the 2
grafts was more than 50% of the predicted FVC of the recipient,
we accepted the size disparity, regardless of the recipient’s diag-
nosis.
Operative Technique
The surgical aspects of LDLLT have been previously described in
detail.4,9 The right and left lower lobes were removed from 2
healthy donors. On the back table, the lobes were flushed with 1 L
of Euro-Collins solution both antegradely and retrogradely from a
TABLE 1. Okayama University triple-drug immunosuppress
Cyclosporine
Before transplantation None
After transplantation Dosage adjusted to maintain trou
3 mo after transplantion
6 mo after transplantion
12 mo after transplantion
Tacrolimus
Before transplantation None
After transplantation Dosage adjusted to maintain trou
3 mo after transplantion
6 mo after transplantion
12 mo after transplantion
Azathioprine
Before transplantation 2 mg/kg
After transplantation 2 mg/kg per d
Mycophenolate mofetil
Before transplantation 500 mg
After transplantation 500-1000 mg twice daily
Corticosteroids
Before reperfusion
After transplantation 3 d after transplantion
6 mo after transplantion
12 mo after transplantion
iv, Intravenous.bag about 50 cm above the table. Then these 2 lobes were im-
934 The Journal of Thoracic and Cardiovascular Surgery ● Deceplanted in the recipient as whole right and left lungs during
cardiopulmonary bypass. The bronchial wrapping with local fat
tissue was performed in patients receiving high-dose steroid ther-
apy. Just before reperfusion, 500 mg to 1 g of methylprednisolone
was administered intravenously, and nitric oxide inhalation was
initiated at 20 ppm. At the conclusion of the operation, a nasal
feeding tube was inserted to the proximal jejunum under the
fluoroscope.
Postoperative Management of the Recipient
The patient was kept intubated for at least 3 days to maintain
optimal expansion of the lobes. Weaning from a ventilator was
intentionally slow, and tracheostomy was performed when pa-
tients showed any signs of sputum retention. Fiberoptic bron-
choscopy was performed every 12 hours during intubation to
suction any retained secretions. An intensive program of chest
physiotherapy was given every 4 hours. The choice of antibi-
otics was based on the results of daily sputum culture. Cyto-
megalovirus prophylaxis with ganciclovir was given to all
recipients for the first 3 months. Postoperative immunosuppres-
sion consisted of triple-drug therapy with cyclosporine (INN:
ciclosporin) or tacrolimus, azathioprine, or mycophenolate
mofetil (MMF) and corticosteroids (Table 1). Induction cyto-
lytic therapy was not used. The combination of cyclosporine,
azathioprine, and steroid was chosen for patients with infectious
lung diseases, pediatric patients, and patients already receiving
steroids; the combination of tacrolimus, MMF, and steroid was
used for other patients. Except for 125 mg of methylpred-
nisolone during the first 3 days, all immunosuppressants were
protocol for living-donor lobar lung transplantation
vel at:
250-350 ng/mL
200-300 ng/mL
150-250 ng/mL
vel at:
10-20 ng/mL
10-15 ng/mL
8-12 ng/mL
Methylprednisolone (iv) 500-1000 mg
Methylprednisolone (iv) 125 mg per d
Prednisone (oral) 0.4 mg/kg per d
Prednisone (oral) 0.2 mg/kg per 2 dive
gh le
gh leadministered through the nasal tube inserted in the proximal
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levels and creatinine clearance, cyclosporine and tacrolimus
trough levels were often reduced to less than the target range.
The immunosuppressant protocol was the same as for our
cadaveric program.
We judged acute rejection on the basis of radiographic and
clinical findings without transbronchial lung biopsy. Early acute
rejection episodes were characterized by dyspnea, low-grade fever,
leukocytosis, hypoxemia, and diffuse interstitial infiltrate on chest
radiographs. A trial bolus dose of 500 mg of methylprednisolone
was administered, and various clinical signs were carefully ob-
served. If acute rejection was indeed the problem, 2 additional
daily bolus doses of methylprednisolone were given. If acute
rejection was encountered more than 3 times, cyclosporine plus
azathioprine was switched to tacrolimus plus MMF. When all
these treatments failed, OKT3 was used.
Long-Term Follow-up of the Recipient
Three months after LDLLT, patients were allowed to return to
their home town. They were asked to keep a diary that included
daily pulmonary function, digital saturation, body temperature,
body weight, blood pressure, and heart rate. The diary was sent to
a lung transplant coordinator every month. Routine full postoper-
ative assessment was performed at 6 months, 12 months, and then
annually.
Results
We performed LDLLT in 30 patients from October 1998
through April 2004. There were 25 female and 5 male
patients, with ages ranging from 8 to 55 years (average, 30.4
years). Six of the patients were children, and 24 were adults.
The recipients’ diagnoses are listed in Table 2. All 10
patients with primary pulmonary hypertension were receiv-
ing high-dose intravenous epoprostenol (average, 89.0 ng ·
kg-1 · min-1). In 5 patients with bronchiolitis obliterans
syndrome (BOS), 3 were after bone marrow transplantation
for leukemia (n  2) and aplastic anemia (n  1), 1 was
after Steven-Johnson syndrome,10 and 1 was caused by
ingestion of Sauropus androgynus.11
The preoperative condition of the 30 recipients is sum-
TABLE 2. Diagnoses for living-donor lobar lung transplan-
tation
Diagnoses No.
Primary pulmonary hypertension 10
Idiopathic interstitial pneumonia 7
Bronchiolitis obliterans 5
Bronchiectasis 3
Lymphangioleiomyomatosis 2
Cystic fibrosis 1
Eisenmenger syndrome 1
Multiple bullae 1
Total 30marized in Table 3. We have accepted patients dependent on
The Journal of Thoracihigh-dose (as high as 50 mg/d prednisone) systemic corti-
costeroid therapy. Five (17%) patients were on a ventilator
at the time of transplantation for as long as 7 weeks (21.2
4.2 days; range, 14-36 days).
Bilateral LDLLT was performed in 29 patients, and right
single LDLLT was performed for a 10-year-old boy with
primary pulmonary hypertension12 because his mother was
the only available donor.
Among the 59 living donors, 5 were non-blood-related
donors (patients’ husbands), and others were blood-related
donors within the second degree. The total FVC of the 2
grafts was estimated to range from 51.4% to 103.0% (av-
erage, 67.1%) of the predicted FVC of the recipient. Sixteen
(53%) patients received an ABO-identical LDLLT, and 14
(47%) patients received an ABO-compatible LDLLT with a
minor ABO mismatch.
Regarding immunosuppressants, the combination of
cyclosporine, azathioprine, and steroid was chosen for 21
(70%) patients, and the combination of tacrolimus, MMF,
and steroid was chosen for 9 (30%) patients. During the
first month, clinically judged acute rejection occurred at
an average rate of 1.5  0.2 episodes per patient. Cyclo-
sporine plus azathioprine was switched to tacrolimus plus
MMF in 4 patients as a result of repeated episodes of
acute rejection. OKT3 was used in 3 patients. Under
careful monitoring of daily serum creatinine levels and
creatinine clearance, cyclosporine and tacrolimus trough
levels were often reduced to less than the target range.
The trough level of cyclosporine was maintained at less
than 250 ng/mL, and that of tacrolimus was maintained at
less than 15 ng/mL during the first 2 weeks (Figure 1).
Except for one patient in whom transient cytomegalovi-
rus enteritis developed, no patient had infectious compli-
cations. There were no bronchial complications in the 59
bronchial anastomoses.
The most frequent complication was lung edema, which
occurred in 6 (20%) patients. Other major complications
included transient peroneal nerve palsy (n  3), renal dys-
function (n  3), hemorrhage necessitating rethoracotomy
(n  2), cardiac tamponade (n  2), kinking of the pulmo-
TABLE 3. Preoperative condition of recipients (n  30)
Preoperative condition No.
Oxygen dependent 30 (100%)
Hospital bound 26 (87%)
Bed bound 22 (73%)
Body mass index 17 17 (57%)
Steroid dependent 15 (50%)
ICU management 13 (43%)
Previous thoracotomy 9 (30%)
Ventilator dependent 5 (17%)nary artery (n  2), hemolytic anemia (n  2), transient
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1). Tracheostomy was required in 15 (50%) patients, rein-
tubation in 7 (23%) patients, rethoracotomy in 3 (10%)
patients, continuous hemodiafiltration in 3 (10%) patients,
and extracorporeal membrane oxygenation in 1 (3%) pa-
tient. The duration of mechanical ventilation required was
15.4 2.8 days, and intensive care unit stay was 23.5 2.9
days. Despite the complicated postoperative course, all 30
patients were discharged without oxygen inhalation after an
average hospital stay of 64.7  4.2 days. Although their
FVC (1396 57 mL, 51.0% of predicted value) was limited
at discharge, arterial oxygen tension on room air (94.2 1.8
mm Hg) and systolic pulmonary artery pressure (24.5 1.2
mm Hg) were excellent.
FVC improved gradually after discharge and reached
1974  87 mL (71.8% of predicted value) at 1 year (Figure
2). The improvement in FVC was associated with the im-
provement in forced expiratory volume in 1 second (FEV1),
indicating that there was no obstructive change in the trans-
planted grafts.
Over the course of this study, 4 patients (16% of 3-month
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Figure 1. A, Cyclosporine trough level during the first month after
LDLLT (n  21). B, Tacrolimus trough level during the first month
after LDLLT (n  9).survivors) had unilateral BOS at 11, 12, 17, and 42 months
936 The Journal of Thoracic and Cardiovascular Surgery ● Deceafter LDLLT, respectively. The contralateral graft was un-
affected in these 4 patients, and their FEV1 decrease stopped
within 9 months.
At the time of final data analysis on April 18, 2004, the
mean time from transplantation to final analysis for the 30
patients was 22.2 months, ranging from 1 to 66 months.
There has been no mortality during the observation period
(Figure 3).
Discussion
The current availability of cadaveric donor lungs has not
been able to meet the increasing demand of potential recip-
ients. As a consequence, efforts have been directed toward
the use of marginal donors,1,2 non–heart-beating donors,3
and living donors.4-8 Bilateral LDLLT was applied at the
University of Southern California (USC) in the early 1990s
as an alternative to cadaveric lung transplantation.4-6 In a
recent report on 123 patients receiving LDLLT, the primary
indication for transplantation was cystic fibrosis (84%).7
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Figure 3. Survival of 30 recipients after LDLLT.
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Figure 2. Changes in FVC and FEV1 after LDLLT.Despite the critical condition of many of these patients, the
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and 5 years, respectively, were comparable with those of
reported bilateral cadaveric lung transplantation from the
International Society for Heart and Lung Transplant regis-
try.13
Encouraged by this work, we applied this procedure to
both pediatric and adult patients in 1998. We recently re-
ported our early results with this procedure in a cohort of 4
pediatric and 10 adult patients. All 14 patients were alive,
with the longest follow-up period of 45 months. We now
have accumulated our experience of LDLLT in 30 patients,
with the longest follow-up period of 66 months.
The optimal immunosuppressive treatment remains
unknown. Our approach to LDLLT recipients focuses on
moderating calcineurin inhibitor levels during the first 2
weeks in the hope of decreasing the risk of infection to
protect renal function and thereby to decrease the risk of
lung edema. Although the target range was 250 to 350
ng/mL for cyclosporine and 10 to 20 ng/mL for tacroli-
mus, the trough level was maintained at less than 250
ng/mL for cyclosporine and 15 ng/mL for tacrolimus,
respectively, during the first 2 weeks, as shown in Figure
1. As a result, no life-threatening infection was encoun-
tered among the 30 recipients. The average serum creat-
inine level remained normal (0.66  0.99 mg/dL) 2
weeks after LDLLT. We avoided intravenous adminis-
tration of immunosuppressants by using a feeding tube
inserted into the proximal jejunum. Enteral administra-
tion of immunosuppressants appeared to be less toxic to
renal function. The feeding tube was also useful for
nutritional support in the early postoperative period.
The high incidence of acute rejection, 1.5  0.2 epi-
sodes per patient, might be related to the relatively low
immunosuppression or to the method of detecting acute
rejection. Transbronchial lung biopsy offers a safe and
accurate means of diagnosis of acute rejection after ca-
daveric lung transplantation and has emerged as the pro-
cedure of choice.14 However, the risk of pneumothorax
and bleeding after transbronchial lung biopsy might be
greater after LDLLT because the small grafts are receiv-
ing the entire cardiac output with undetectable dead
space. Thus we judged acute rejection on the basis of
radiographic and clinical findings.
There are several important concepts in the respiratory
management of LDLLT recipients because of the small
size of the implanted lungs. We wean the patients from a
ventilator very slowly so that the small lobes can main-
tain optimal expansion. FVC measured immediately be-
fore extubation was only about 500 mL in general. If the
patients show any sign of sputum retention, we reintubate
and perform a tracheostomy without hesitation. The av-
erage duration of mechanical ventilator use was more
than 2 weeks, and tracheostomy was required for half of
The Journal of Thoracithe recipients. It should also be noted that the early
tracheostomy made it possible to wean the recipients
from the ventilator very slowly. Frequent use of a fiber-
optic bronchoscope and an intensive program of chest
physiotherapy appeared to be important in decreasing the
risk of infection. Because a limited amount of vascular
bed was implanted in LDLLT, nitric oxide inhalation was
routinely used to decrease the risk of pulmonary hyper-
tension and lung edema.
The history of lung transplantation in Japan is short
because of society’s difficulty in accepting the concept of
brain death. The transplant law was finally passed, and
the first successful cadaveric lung transplantation was
performed in March 2000. We could perform only 4
cadaveric lung transplantations in our institution com-
pared with 30 LDLLTs because of the scarcity of avail-
able cadaveric donors. However, we have accepted only
critically ill patients for LDLLT because of the possible
serious morbidity associated with donor lobectomy.15
The preoperative condition of the 30 LDLLT recipients
was very poor, as summarized in Table 3. Most of the
patients (73%) were bed bound, and 5 (17%) were sup-
ported by ventilators. The USC group recently reported
that patients on ventilators preoperatively had signifi-
cantly worse outcomes.7
In our series the reasons for transplantation have in-
cluded hypertensive (n  11, 37%), obstructive (n  8,
27%), restrictive (n  7, 23%), and infectious (n  4, 13%)
lung diseases.
Because cystic fibrosis is rare in Japan, it was the indi-
cation in only 1 (3%) patient compared with in 84% of the
patients in the USC series.7 Of note, infection was the
predominant cause of death (53%) in their report.
BOS has been the major obstacle after lung transplan-
tation.13,16,17 The question remains of whether patients
receiving LDLLT will have less BOS than those receiv-
ing conventional cadaveric lung transplantation. Starnes
and colleagues18 reported that LDLLT recipients had less
BOS than cadaveric lung transplant recipients in the
pediatric population. Interestingly, all 4 patients with
BOS in our study had unilateral BOS, and their FEV1
decrease stopped within 9 months. The different antige-
nicity between 2 LDLLT grafts might explain this phe-
nomenon.
Despite poor preoperative condition and complicated
early postoperative course, all recipients were sent home
without the need for oxygen inhalation. Their quality of
life was excellent, along with the improvement in pul-
monary function. Although our experience with LDLLT
is still limited in terms of both numbers (n  30) and
observation period (1-66 months), 100% survival during
the observation period is noteworthy. We believe that
enteral administration of low-dose immunosuppressants,
c and Cardiovascular Surgery ● Volume 128, Number 6 937
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biopsy, and slow weaning from a ventilator were effec-
tive strategies for LDLLT during the early postoperative
period. The 2 lobes obtained from 2 different donors
appear to be beneficial in the long term because contralat-
eral unaffected lung might act as a reservoir in the case of
unilateral BOS. We conclude that LDLLT might provide
better survival than conventional cadaveric lung trans-
plantation.
We acknowledge the excellent advice on our patient care
obtained from Elbert P. Trulock, MD (Washington University
School of Medicine), and Mark L Barr, MD (University of South-
ern California).
REFERENCES
1. Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock EP,
Cooper JD, et al. Successful outcome of lung transplantation is not
compromised by the use of marginal donor lungs. J Thorac Cardio-
vasc Surg. 1995;109:1075-9.
2. Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH.
Marginal donor lungs. A reassessment. J Thorac Cardiovasc Surg.
2002;123:421-8.
3. Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L.
Transplantation of lungs from a non-heart-beating donor. Lancet.
2001;357:825-9.
4. Starnes VA, Barr ML, Cohen RG. Lobar transplantation: indication,
technique, and outcome. J Thorac Cardiovasc Surg. 1994;108:403-11.
5. Starnes VA, Barr ML, Cohen RG, Hagen JA, Wells WJ, Horn MV, et
al. Living–donor lobar lung transplantation experience: intermediate
results. J Thorac Cardiovasc Surg. 1996;112:1284-91.
6. Starnes VA, Barr ML, Schenkel FA, Horn MV, Cohen RG, Hagen JA,
et al. Experience with living–donor lobar transplantation for indica-
tions other than cystic fibrosis. J Thorac Cardiovasc Surg. 1997;114:
917-22.
7. Starnes VA, Bowdish ME, Woo MS, Barbers RG, Schenkel FA, Horn
MV, et al. A decade of living lobar lung transplantation: recipient
outcomes. J Thorac Cardiovasc Surg. 2004;127:114-22.
8. Date H, Aoe M, Nagahiro I, Sano Y, Andou A, Matsubara H, et al.
Living–donor lobar lung transplantation for various lung diseases.
J Thorac Cardiovasc Surg. 2003;126:476-81.
9. Cohen RG, Barr ML, Schenkel FA, DeMeester TR, Wells WJ, Starnes
VA. Living–related donor lobectomy for bilateral lobar transplantation
in patients with cystic fibrosis. Ann Thorac Surg. 1994;57:1423-8.
10. Date H, Sano Y, Aoe M, Goto K, Tedoriya T, Sano S, et al. Living–
donor lobar lung transplantation for bronchiolitis obliterans after
Stevens-Johnson syndrome. J Thorac Cardiovasc Surg. 2002;123:389-
91.
11. Hsu H, Chang H, Goan Y. Intermediate results in Sauropus androgynus
bronchiolitis obliterans patients after single-lung transplantation. Trans-
plant Proc. 2000;32:2422-3.
12. Date H, Sano Y, Aoe M, Matsubara H, Kusano K, Goto K, et al.
Living–donor single lobe lung transplantation for primary pulmonary
hypertension in a child. J Thorac Cardiovasc Surg. 2002;123:1211-3.
13. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Mohacsi PJ, Keck
BM, et al. The registry of the International Society for Heart and Lung
Transplantation. Twentieth official adult lung and heart-lung transplant
report—2003. J Heart Lung Transplant. 2003;22:625-35.
14. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper
JD. The role of transbronchial lung biopsy in the treatment of lung
transplant recipients: an analysis of 200 consecutive procedures. Chest.
1992;102:1049-54.
15. Battafarano RJ, Anderson RC, Meyers BF, Guthrie TJ, Schuller D,
Cooper JD, et al. Perioperative complications after living donor lobec-
tomy. J Thorac Cardiovasc Surg. 2000;120:909-15.16. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, et
al. Obliterative bronchiolitis after lung and heart-lung transplantation:
938 The Journal of Thoracic and Cardiovascular Surgery ● Decean analysis of risk factors and management. J Thorac Cardiovasc
Surg. 1995;110:4-13.
17. Date H, Lynch JP, Sundaresan S, Patterson GA, Trulock EP. The
impact of cytolytic therapy on bronchiolitis obliterans syndrome.
J Heart Lung Transplant. 1998;17:869-75.
18. Starnes VA, Woo MS, MacLaughlin EF, Horn MV, Wong PC, Row-
land JM, et al. Comparison of outcomes between living donor and
cadaveric lung transplantation in children. Ann Thorac Surg. 1999;68:
2279-84.
Discussion
Dr John C. Wain, Jr (Boston, Mass). Dr Date, congratulations to
you. It is really a remarkable series with that survival in those
patients. The experience is remarkable not only because of the
survival, but I think your recipient population is unique in terms
of the high incidence of pulmonary hypertension. Most of the
patients, of course, have nonseptic lung disease. In addition, in
the manuscript you mentioned that all patients received inhaled
nitric oxide as part of their perioperative management, which is
certainly somewhat novel. The empiric diagnosis, if you will, of
acute rejection at first sounds unique, but, as I thought about it,
most of the time you make the diagnosis on clinical grounds
anyway. I think you are to be commended for emphasizing that
point as well. On the other hand, the lack of late graft dysfunc-
tion from BOS is really quite remarkable, as is the fact that, as
you pointed out in your presentation, it appears to stabilize in
the unilateral sense after a period of time.I have several ques-
tions about all of this, and I hope to gain some insights in
managing our own patients. First, you contend that the postop-
erative ventilation with low lung volumes contributes to your
improved outcomes, and well it might. Certainly there is a large
body of literature that suggests that overdistension of the lung
leads to concomitant lung injury. However, in our own experi-
ence with 15 of these patients, we have observed that lung
injury often is manifested immediately after reperfusion, right
in the operating room. I was wondering, with regard to that and
the subsequent postoperative ventilation, whether you have any
specific algorithm for reinflation and reperfusion of the lung
grafts in the operating room.
Dr Date. At the time of reperfusion, we try to make sure there
is no atelectasis left in the small grafts transplanted. Because of the
small grafts we transplanted, if you have a small amount of
atelectasis, your Po2 will be very low. Therefore, we make sure
that the lung is well expanded.
Dr Wain. What sort of inflation pressures do you use both in
the operating room and then postoperatively?
Dr Date. The maximal ventilation pressure should be less than
20 mm Hg. Therefore, our tidal volume is usually around 200 to
250, very small.
Dr Wain. Are you managing patients with volume ventilation
or pressure-limited ventilation? How do you do that?
Dr Date. Our intensive care unit staffs handle that, so I do not
know. I am sorry.
Dr Wain. That’s fine. In terms of the nitric oxide, is that started
in the operating room, or when is that initiated?
Dr Date. The first ventilation going into the transplanted lung
contains nitric oxide.
Dr Wain. With regard to the rejection issues, do you have any
MHC data on these patients to look at? For instance, do the
patients who have acute rejection have more than one episode or
mber 2004
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matching?
Dr Date. As I said, our acute rejection was just based on
clinical and radiographic findings. Therefore, only 40% of the
patients had radiographically evident acute rejection, and usually
those are only unilateral lung. There is also good information to
differentiate it between rejection and infection in this particular
group of patients.
Dr Wain. With regard to the acute rejection, was there any
difference in the unrelated versus the related donors?
Dr Date. Thus far, no.
Dr Wain. In regard to the unilaterality of it, was there a
preponderance of that on the right side with reference to the
possibility of reflux and aspiration?
Dr Date. There was no difference between the right side and
the left side.
Dr Wain. Last, what is your conjecture about the long-term
BOS or lack thereof in these patients? Is it because of a short
ischemic interval on the donor side? Is it because of less lung
inflammation up front? Is it because of the nitric oxide?
Dr Date. We do not know. Still, we are not sure whether
LDLLT will have a lower incidence of BOS compared with
cadaveric lung transplantation. I think the follow-up period is too
short to make a final conclusion.
Dr Wain. The cadaveric transplantations that you do, do you
manage them in the same way in terms of limiting ventilation and
nitric oxide and so on?
Dr Date. Basically, yes. Because we get used to handling it this
way, it is easier for us to handle it in the same way for cadaveric
lung transplantation as well.
Dr Wain. Right. Stick with the system. Well, it obviously
works, and congratulations.
Dr Erino A. Rendina (Rome, Italy). First of all, congratula-
tions, Dr Date. These results are really impressive.
I would like you to comment on one issue. You say in your
abstract that you use relatively low-dose immunosuppressants, and
yet, according to that, you have reported no infection in the early
postoperative period in your patients. Therefore, you seem to favor
control of infection over vigorous early immunosuppression. Do
you want to comment on what the destiny in terms of the risk of
BOS will be for these patients?
Dr Date. Erino, that is an excellent question. We believe that
preventing infection is more important than preventing acute
rejection in the early period because acute rejection rarely is the
cause of death in the early period. However, the average rate of
acute rejection per patient is 1.5, which seems to be higher than
in the other report, and we are not sure whether that will
correlate with the higher incidence of BOS in the future. Time
will tell.
Dr Bryan F. Meyers (St Louis, Mo). Hiroshi, congratulations
on a terrific report and experience. I also congratulate your col-
leagues at Okayama University who have supported you in this.
The ratio of living-donor lobar transplants to cadaveric transplants
is striking, and it is out of proportion to what we are used to
hearing about. Could you elaborate a little bit about the cultural
situation with regard to cadaveric donors in Japan and how that
might have influenced your ratio?
The Journal of ThoraciDr Date. We do have a cadaveric lung transplant program, but
the Japanese transplant law is the strictest in the world. It is not
only a cultural problem, but many other issues are also involved.
If the transplant law is going to be changed in the future and if we
have a larger number of cadaveric lung transplants, the proportion
between the cadaveric and LDLLTs will be changed.
Dr Vaughn A. Starnes (Los Angeles, Calif). Dr Date, it was an
excellent paper with excellent results, and we strive to meet your
results. After about 10 years in the business, I can tell you that our
results are nowhere near yours. But it begs the question, with your
excellent results and probably the worst recipients that you could
think of, are you now going to offer this more electively to other
patients?
Dr Date. Thank you very much, Dr Starnes. Certainly without
your pioneering work, I would not be standing here. At this time,
we are not at the stage of offering this procedure to less diseased
patients because of the possible serious complications. We did
have 2 rethoracotomies in donors, and we did have one patient who
experienced empyema requiring a chest tube and irrigation. There-
fore, we offer this only to very critically ill patients at the moment.
Dr Starnes. I have a comment about the reperfusion stage. I
think that is probably the most critical stage in the operation,
and the use of cardiopulmonary bypass actually helps you with
that in terms of being able to come off very empty. As for our
cardiac outputs and indexes, usually the first 4 to 8 hours is very
low; I suspect that that is the reason you are also using nitric
oxide to enhance or advance or increase the recruitment of the
microvasculature of the lung bed because it really does help. I
do not think it really has any “protective effect” other than
vasodilatory.
Dr Federico Venuta (Rome, Italy). Congratulations, Dr Date,
on your presentation. Which solution did you use to preserve your
lungs, and did you flush them only antegradely or did you also use
the retrograde flush at the time of harvesting?
Dr Date. We use Euro-Collins solution because Perfadex is not
available yet, and we use an antegrade flush for about two thirds,
and for the last third, we use a retrograde flush, according to your
report.
Dr Duane R. Davis, Jr (Durham, NC). Hiroshi, congratula-
tions again on a very impressive series.
I have a couple of questions. How much will you bend the rules
in terms of your donor-recipient matching because you do not have
access to cadaveric donors? The second question gets into your
reperfusion injury. You had about a 20% incidence. Was that more
associated with having a small lobe going into a large individual or
was it more associated with your pulmonary hypertension status
beforehand?
Dr Date. The first question you mentioned is how often we
reject the recipient according to the donor and recipient size
mismatching.
Dr Davis. Obviously if you are stuck with an adult and you do
not have a good-sized donor— and I think Vaughn says 4 inches,
you know, we bend the rules some—how much do you bend?
Dr Date. We accept only when the estimated FVC of the 2
grafts exceeds 45% to 50% of the predicted FVC of the recip-
ient. Therefore, we have turned down many patients because of
the size disparity. In particular, male adult patients will have
very little chance to receive this operation. We have only one
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regarding the lung edema, we have only one patient who had a
real acute lung edema immediately after reperfusion, and 5940 The Journal of Thoracic and Cardiovascular Surgery ● Decetransplantation, and those are the patients with primary pulmo-
nary hypertension. Therefore I think that is not only related to
the volume of the lung but also related to the cardiac functionother patients had lung edema between 5 and 10 days after of the patient.mber 2004
